Two different molecular genetic methods were compared for their suitability for monitoring minimal residual disease in patients with follicular lymphoma (FL) treated with high-dose therapy and autologous stem cell transplantation. Fifteen patients were selected because of a specific PCR-amplifiable t(14;18) mbr translocation. PCR amplification of rearrangements of the complementary region III (CDRIII) of the immunoglobulin heavy chain gene was also carried out. After autologous stem cell transplantation, patients were prospectively monitored with both molecular genetic methods. Seven of the 15 patients with detectable t(14;18) prior to transplantation were persistently negative during follow-up to 32 months post transplant. None of these patients relapsed, whereas four of eight patients with positive PCR signals post transplant relapsed. Comparing t(14;18) and PAGE results, we observed six patients showing clonal signals in CDRIII PAGE in spite of persistent negativity of t(14;18) PCR. We concluded that in patients with FL, t(14;18) PCR is superior to CDRIII PCR in terms of sensitivity and specificity. A positive t(14;18) PCR during the first year post transplant is highly predictive for disease recurrence. CDRIII PCR may be used for monitoring in t(14;18) negative lymphomas. However, due to the poor specificity of conventional gel electrophoresis PCR, the use of clone-specific probes is highly desirable. Keywords: molecular monitoring; stem cell transplantation; lymphoma; PCR; CDRIII; t(14; 18) Autologous stem cell transplantation (ASCT) is increasingly being used for treatment of patients with advanced follicular lymphomas (FL).
patients continue to relapse without development of a plateau on Kaplan-Meier plots. [1] [2] [3] In order to identify patients at risk for clinical relapse early, sensitive techniques to detect minimal residual disease are urgently needed. To this end a variety of polymerase chain reaction (PCR)-based molecular strategies have been developed. These include detection of the FLassociated t(14;18) translocation [1] [2] [3] and the amplification of clonal complementary-determining regions I-III (CDR) rearrangements followed by gel electrophoresis. 5 Although promising correlations between the molecular status and the clinical course have been reported for each of these techniques, 1, 3, [6] [7] [8] both methods have their limitations. The translocation t(14;18)(q32;q21), which juxtaposes the Bcl-2 oncogene on chromosome 18 to the Ig heavy chain (IgH) locus on chromosome 14, is present in the majority of patients with FL. 9, 10 However, a PCRdetectable t(14;18) can be found in only 50-75% of cases with FL, 11 implying that this monitoring strategy is inappropriate for an important fraction of patients.
During B cell maturation three different germline gene segment families (variable = V; diversity = D; joining = J) of the IgH gene undergo specific rearrangements. One result of this process is the third complementary determining region (CDRIII) which encodes for one of three CDR regions of the heavy chains. By insertion of non-coding N regions between the rearranged gene segments a highly variable sequence (VH-N-DH-N-JH) is generated, which is unique for each individual B cell clone. [12] [13] [14] Using primers annealing for conserved sequences within the V and J regions, the CDRIII rearrangement can be amplified by a hot start PCR. Although, in theory, a tumor-specific CDRIII sequence should always be present, it is not possible to find consensus primers that are capable of amplifying all possible V-D-J combinations. 6 In addition, the detection of the tumour-specific CDRIII signal may be difficult due to the concurrent amplification of CDRIII rearrangements of normal B cells, leading to a polyclonal background masking the specific signal. Thus, depending on the number of nonmalignant B cells in the sample, the CDRIII PCR followed by separation of the amplified DNA fragments by agarose gel electrophoresis may be able to detect one tumor cell in not more than 100 normal cells. 5, 6 The resolution potential of DNA amplificate separation may be increased by using polyacrylamide gel electrophoresis (PAGE). 15 In the present paper, we have compared t(14/18) and CDRIII PCR with regard to their suitability for monitoring of minimal residual disease in bone marrow (BM) or peripheral blood (PB) samples of 15 patients with disseminated FL following ASCT.
Materials and methods

Patients
Between December 1992 and May 1997, 15 patients (four females, 11 males) selected for the presence of PCR amplifiable t(14;18) mbr translocation were referred for autografting for stage III or IV FL according to the REAL classification. 16, 17 The median age was 43 (27-53) years. Further details of patient characteristics are given in Table 1 . Written informed consent using institutionally approved forms was obtained from each patient treated according to this protocol.
PBPC mobilisation, collection and CD34
+ selection . In patient UPN 10 a B cell depletion was performed with the MaxSep system. The unmanipulated or purged leukapheresis products underwent programmed freezing and were cryopreserved in liquid nitrogen until the day of reinfusion.
High-dose chemotherapy and progenitor cell reinfusion
Myeloablative therapy consisted of fractionated total body irradiation (TBI) with 2 Gy administered twice daily on 3 were mixed with aqua bidist. Oligonucleotide primers were synthesized according to published sequences and purified by high pressure liquid chromatography by a commercial supplier (Biometra, Göttingen, Germany). Primers were used as published and are listed in Table 2 .
For the first round of CDRIII amplification using primers FR3A and LJH after an incubation time of 11 min at 94°C tubes were subjected to 30 serial cycles of denaturation (1 min at 94°C), annealing (30 s at 55°C), and extension (30 s at 72°C) in a conventional thermocycler with a heat lid (UNO; Biometra). After the last cycle a post-elongation step was performed (7 min at 72°C). For the second round (semi-nested PCR) 0.5 l of a 1:20 dilution of the amplification product was used as template with primers FR3A and VLJH. Tubes were subjected after 11 min of incubation at 94°C to 20 serial cycles of denaturation (1 min at 94°C), annealing (15 s at 58°C), extension (30 s at 72°C) and a post-elongation step (72°C for 7 min). Negative and positive controls were included in each assay. CDRIII PCR Table 2 Nucleotide sequence of primers used in CDRIII and t(14;18) PCR
Primer
Primer sequence (5′ → 3′) Localization Ref. FR3IgH  20  GTATT ACTGT  LJH  TGAGG AGACG GTGAC C  JH-external  20  VLJH  GTGAC CAGGG TNCCT TGGCC  JH-internal  02  CCAG  JH(14;18) GGTGA CCAGG GTCCC TTGGC  JH-region  21  CCCAG  Bclout  GGAAT TCCGC ATTTA ATTCA  bcl2-gene  21  TGGTA TTCAG GAT  Bclin  CGTGG CCTGT TTCAA  bcl2-gene  21 amplification products were separated on a non-denaturating polyacrylamide gel (T = 10%; C = 2%; Clean Gel; Pharmacia, Freiburg, Germany). Bands were visualized by silver staining. This method allows detection of DNA with a sensitivity of 0.5-2 ng DNA per band.
FR3A ACACG GC(C/T)(G/C)T
Analysis of MBR chromosomal translocation t(14;18)
Amount of DNA, PCR buffer, primers and enzyme concentrations was identical as in the reaction mix for amplification of CDRIII rearrangements except that no hot start PCR was performed. Oligonucleotide primers are given in Table 2 . After 7 min at 92°C 2.5 U Taq Polymerase were added to the PCR mixture and overlayed with 30 l mineral oil (Sigma, München, Germany). For the first round of t(14;18) amplification using primers JH1418 and bclout PCR tubes were subjected to 30 serial cycles of denaturation (1 min at 92°C) and annealing/elongation (30 s at 65°C). After the last cycle an elongation step (7 min at 65°C) was performed. For the second round 1 l of the 1:20 in aqua bidest diluted amplification product were used as template with primers JH1418 and bclin and subjected to 30 cycles. Ten l of the translocation t(14;18) amplification products were separated in a 2% agarose gel (Gibco BRL, Eggenstein, Germany), stained with ethidium bromide and photographed under UV illumination.
Direct sequencing of the t(14;18) MBR region
After PCR, ethidium bromide-stained bands of interest were excised from a 2% agarose gel under long-wave UV illumination. DNA was extracted with the Quiaquick column system (Quiagen). 500 fmol of product were sequenced according to the dideoxy chain determination method via cycle sequencing (Sequitherm Cycle Sequencing Kit; Biozym, Hameln, Germany) following the manufacturer's protocol. The 35 S-dATP-labeled sequencing products were analysed by autoradiography after electrophoretic separation on a 6% denaturating polyacrylamide gel. Control of t(14;18)-specific DNA during further investigations was performed using oligonucleotides (20 nt long) spanning the clone-specific bcl2-N-JH regions. Oligonucleotides were synthezised by a commercial supplier (Pharmacia). PCR products were dot blotted after denaturation on a Hybond N+ membrane (Amersham) using a dot blot apparatus (Biometra). Probes were 3′-end labelled with fluorescein. Detection of clone-specific DNA was done using the enhanced chemoluminescence procedure following the manufacturer's protocol (ECL Kit; Amersham, Braunschweig, Germany).
Evaluation of sensitivity
PCR strategies were evaluated for their sensitivity with cell line dilution experiments. The Burkitt lymphoma cell line Ramos was used for estimation of CDRIII sensitivity. Ramos cells were diluted in human mononuclear cells in decreasing concentrations (100%, 10%, 1%, 0.1%, 0.01%). The detection limit of the CDRIII PCR (PAGE) was one tumor cell in 10 3 to normal cells (Figure 1 ). The limit of the t(14;18) PCR was one tumor cell in 10 5 normal cells. Evaluation of the detection limit was done with the cell line Karpas 422 (kindly provided by A Karpas, Cambridge, UK) (data not shown).
Results
Identification of the tumor marker
All patients investigated here showed a PCR-amplifiable MBR translocation t(14;18) in bone marrow and/or peripheral blood samples obtained prior to autografting. After sequencing, it was possible to identify an N region between the chromosomes 18 and 14 in all patients. The medium length of the N region was 10 nucleotides. N region-specific probes were constructed and proved to be complementary to the amplification products obtained during monitoring in each individual case. Using FR3/JH consensus primers, clonal rearrangements were detectable in all patients in bone marrow and/or peripheral blood by CDRIII PCR prior to transplant. In 6/15 patients an oligoclonal pattern was obtained with PAGE; the signal of highest intensity was assumed to represent the tumour cell clone.
Tumor cell contamination of the graft
A tumor-specific or clonal signal was detectable in 12/15 grafts using t(14;18) PCR. In 3/15 patients (UPN 05, 06 and 14), transplanted with CD34 + selected grafts, no t(14;18) signal was detectable in the CD34-positive fraction. Using CDRIII PCR, clonal products were obtained in all purged or unpurged grafts.
Results of molecular monitoring post transplant
In patients with a PCR-detectable translocation t(14;18) two distinct patterns were observed after transplantation. One group consisted of 11 patients who either never showed a t(14;18)-specific PCR signal post transplant (UPN 01, 02, 06, 07, 09, 10, 11) or had a positive t(14;18) PCR signal only during the first few weeks after autografting and remained persistently negative during further follow-up up to 36 months post transplant (UPN 03, 04, 05, 08). None of these patients relapsed. Another four patients had persistently positive PCR signals later than 2 months post transplant. All patients of this group experienced a clinical relapse at 3 (UPN 15), 7 (UPN 14, Figure 2 ), 10 (UPN 13) and 35 months (UPN 12) post transplant. Using the CDRIII PCR clonal signals were not found or detectable only during the first 3 months post transplant in nine of 15 patients tested (patient 03, Figures 3 and 4) . After 3 months, clonality disappeared and polyclonal signals became detectable. The remaining six patients continued to have clonal signals after 6 months post autografting ( Figure 5 ). Four of these patients have relapsed so far.
Comparison of t(14;18) and CDRIII PAGE results
In five patients, the results of the CDRIII analysis were in agreement with the corresponding t (14;18) plantation whereas the results of the CDRIII PCR were polyclonal.
Discussion
Monitoring of MRD after autologous stem cell transplantation is an important tool in evaluating the efficacy of this new treatment modality for patients with follicular lymphoma. The detection of translocation t(14;18) or of the clone-specific heavy chain region CDRIII can both be used to trace MRD in patients with FL carrying the translocation t(14;18 1, 3, 5, 9 We were able to demonstrate clonal CDRIII rearrangements with consensus FR3 and JH primers in all patients examined although samples with high tumour cell contamination were available only for a minority of patients. The higher resolution potential of polyacrylamide gel electrophoresis might have unravelled monoclonal or oligoclonal B cell populations secondary to infections or might have monitored the evolution of the B cell system after high-dose therapy, instead of detecting a tumor-specific clone. This hypothesis would explain why clonal amplifications were found in each individual patient. The fact that 14/15 patients including those with negative bcl-2/IgH PCR showed clonal CDRIII signals during the first 3 months immediately post transplant supports this view. This phenomenon is probably due to the oligoclonal recovery of the immune system after myeloablation 13 and not to persisting tumour cells. Sensitivity and specificity of CDRIII PCR appear to be inferior to that of bcl-2/IgH PCR, because (1) no clinical relapse occurred in 2/6 CDRIII-positive patients (UPN 10 and 11); and (2) in patients 14 and 15 the results of the CDRIII PCR showed no clonal signal at the time of clinical relapse whereas the t(14;18) PCR was positive. To improve the predictive value of CDRIII PCR it seems to be necessary to clone and sequence the CDR regions. For this approach it is important to receive peripheral blood or bone marrow with an informative number of tumour cells. After starting therapy the number of tumour cells obviously is reduced implying that the tumour clone-specific CDRIII rearrangement can only be distinguished from the natural pattern of clonal rearrangements by either probing the tumour clone-specific V-N-D-N-Jregion with a labelled oligonucleotide or by PCR amplification with an allele-specific primer for that region. During the annealing step in the PCR the primers compete with all present CDRIII regions. That means that the amplification of the CDRIII regions of all B cells will result in a polyclonal background smear covering the 90-120 nt region of the polyacrylamide gel. A very low number of non-malignant B cells will result in single bands, thus mimicking a clonal tumour cell population. Therefore single non-malignant B cells cannot reliably be distinguished by a CDRIII PCR approach from tumour cells. Taken together, our data suggest that in patients with FL, bcl-2/IgH PCR is superior to CDRIII PCR in terms of sensitivity and specificity and should be preferred for molecular monitoring whenever possible. A persistently or intermittently positive t(14;18) PCR during the first year post transplant is highly predictive of disease recurrence. CDRIII PCR may be used for monitoring in t(14;18)-negative lymphomas. As the number of patients is small and follow-up is limited, final conclusions with regard to the clinical importance of the contamination of the graft with very low numbers of tumour cells only detected by molecular tools, awaits further study. Due to the poor specificity of conventional gel electrophoresis after CDRIII PCR, the use of clone-specific probes is highly desirable. This approach, however, requires the availability of samples containing sufficient lymphoma cells to allow adequate identification of the tumour clone. Therefore, PB and/or BM samples should be collected and cryopreserved at the time of diagnosis from all patients with FL who may become candidates for ASCT.
